Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Journal of Clinical Lipidology
|
June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Christie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Michael H Davidson, Michael Szarek, Philip Scheltens, et al.
Journal of Atherosclerosis and Thrombosis
|
April 3, 2024
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
Mariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, et al.
American Journal of Preventive Cardiology
|
July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
Adam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.
Journal of Biotechnology
|
May 7, 2026
Leveraging Mixed-Mode Filter During Cell Culture Harvest to Prevent Antibody Reduction
Zhenshu Wang, Michael Hartmann, Geetanjali Pendyala, et al.
JCO Precision Oncology
|
January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
Heather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
Prostate Cancer and Prostatic Diseases
|
December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Michael T Schweizer, Roman Gulati, Todd Yezefski, et al.
American Heart Journal
|
May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
The New England Journal of Medicine
|
May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Journal of Clinical Lipidology
|
June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Christie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Michael H Davidson, Michael Szarek, Philip Scheltens, et al.
Journal of Atherosclerosis and Thrombosis
|
April 3, 2024
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
Mariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, et al.
American Journal of Preventive Cardiology
|
July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
Adam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.
Journal of Biotechnology
|
May 7, 2026
Leveraging Mixed-Mode Filter During Cell Culture Harvest to Prevent Antibody Reduction
Zhenshu Wang, Michael Hartmann, Geetanjali Pendyala, et al.
JCO Precision Oncology
|
January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
Heather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
Prostate Cancer and Prostatic Diseases
|
December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Michael T Schweizer, Roman Gulati, Todd Yezefski, et al.
American Heart Journal
|
May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
The New England Journal of Medicine
|
May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Page
of 4